Asset sale Announced Sponsor exit

DRI Healthcare Trust acquisition of Royalty participation rights in U.S. net sales of tavapadon

US$316m consideration

Announced 21 Sep 2026

Advisers

Royalty participation rights in U.S. net sales of tavapadon

Target

Not disclosed

Target
Royalty participation rights in U.S. net sales of tavapadon
Acquirer
DRI Healthcare Trust
Target based in
United States
Buyer based in
Canada
Seller based in
United States
Sector
Specialty finance and leasing
Tags
Specialty finance and leasing, Pharma, Asset & Wealth Management

In the league tables

Similar deals

All specialty finance and leasing deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.